Publikace
- Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance2021 | Farmaceutická fakulta v Hradci Králové
- Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme2020 | Farmaceutická fakulta v Hradci Králové
- Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C32020 | Farmaceutická fakulta v Hradci Králové
- Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile2018 | Farmaceutická fakulta v Hradci Králové
- Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro2018 | Farmaceutická fakulta v Hradci Králové
- Purvalanol A, Olomoucine II and Roscovitine Inhibit ABCB1 Transporter and Synergistically Potentiate Cytotoxic Effects of Daunorubicin In Vitro2013 | Farmaceutická fakulta v Hradci Králové
- Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo2023 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
Loading network view...